Serum NT-proBNP level for predicting functional outcomes after acute ischemic stroke
Authors:
Open Access
- 25 August 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Abstract
N-terminus pro-brain natriuretic peptide (NT-proBNP) has been studied and recognized as a biomarker of cardiac thrombogenicity and stroke risk. However, the association between NT-proBNP and functional outcomes following acute ischemic stroke is still debated. This study aimed to investigate whether serum NT-proBNP level is associated with functional outcomes in acute ischemic stroke individuals. This prospective cohort study included patients diagnosed with acute ischemic stroke, and serum NT-proBNP levels were measured within 72 h. At 3 months, all patients were followed up for a modified Rankin Scale (mRS), and logistic regression models were used to evaluate the association of NT-proBNP on the primary outcome, in which a score of 3–6 was classified as an unfavorable functional outcome. Sixty-seven patients were enrolled in the study, and 23 (34.3%) patients were identified with an unfavorable functional outcome. Elevated serum NT-proBNP levels (> 100 pg/mL) were observed in 57 (85.1%) patients, and the Youden index demonstrated a cutpoint estimation of poor outcomes at 476 pg/mL with 74% sensitivity and 63% specificity. Multivariate regression analysis showed an elevation of NT-proBNP above the cutpoint level was an independent predictor for unfavorable functional outcomes, odds ratio 3.77, 95% confidence interval (1.04–13.62), P = 0.04. The present study demonstrated that elevated serum NT-proBNP levels were expected among acute ischemic stroke patients and represented the risk of unfavorable functional outcomes, suggesting that NT-proBNP might be a useful biomarker for predicting prognosis after ischemic stroke.Keywords
Funding Information
- Faculty of Medicine Research Fund, Chiang Mai University (8312-2564)
This publication has 32 references indexed in Scilit:
- Amino Terminal Pro–B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic TherapyStroke, 2013
- Molecular Biomarkers in Stroke Diagnosis and PrognosisBiomarkers in Medicine, 2009
- Plasma brain natriuretic peptide as a surrogate marker for cardioembolic strokeBMC Neurology, 2008
- Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical TrialsStroke, 2007
- N-Terminal Pro-Brain Natriuretic Peptide Levels Are Elevated in Patients with Acute Ischemic StrokeAngiology, 2005
- Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routineHeart, 2005
- Natriuretic Peptides and Mortality After StrokeStroke, 2005
- Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide in Acute Ischemic Stroke Do Not Relate to Clinical PrognosisStroke, 2005
- Improving the Assessment of Outcomes in StrokeStroke, 2002
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993